By Role
Subscriptions
Continuing Education
- One Health
- Pain Management
- Oncology
- Geriatric & Palliative Medicine
- Ophthalmology
- Anatomic Pathology
- Poultry Medicine
- Infectious Diseases
- Dermatology
- Theriogenology
- Nutrition
- Animal Welfare
- Radiology
- Internal Medicine
- Small Ruminant
- Cardiology
- Dentistry
- Feline Medicine
- Soft Tissue Surgery
- Urology/Nephrology
- Avian & Exotic
- Preventive Medicine
- Anesthesiology & Pain Management
- Integrative & Holistic Medicine
- Food Animals
- Behavior
- Zoo Medicine
- Toxicology
- Orthopedics
- Emergency & Critical Care
- Equine Medicine
- Pharmacology
- Pediatrics
- Respiratory Medicine
- Shelter Medicine
- Parasitology
- Clinical Pathology
- Virtual Care
- Rehabilitation
- Epidemiology
- Fish Medicine
- Diabetes
- Livestock
- Endocrinology
Interactive case 14: The case of the nighttime food thief
Correct. It would seem to make sense to increase Ivy's trilostane dose at this time because her post-ACTH cortisol concentration is above the goal range of 5.4 to 9.1 µg/dl. However, cortisol concentrations in patients receiving trilostane and showing improvement in clinical signs may continue to decrease during this initial phase of treatment.3 So if clinical signs improve and the ACTH stimulation test does not indicate hypoadrenocorticism (monitoring for insufficient cortisol response is the primary reason for this first test), then it would be best to not alter the dose now.
Click here to continue.
Related Videos
Related Content
